Metabolically Healthy Obesity
Open accessThe DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Obesity contributes to reduced life expectancy, impaired quality of life, and disabilities, mainly in those individuals who develop cardiovascular diseases, type 2 diabetes, osteoarthritis, and cancer. However, there is a large variation in the individual risk to developing obesity-associated comorbid diseases that cannot simply be explained by the extent of adiposity. Observations that a proportion of individuals with obesity have a significantly lower risk for cardiometabolic abnormalities led to the concept of metabolically healthy obesity (MHO). Although there is no clear definition, normal glucose and lipid metabolism parameters—in addition to the absence of hypertension—usually serve as criteria to diagnose MHO. Biological mechanisms underlying MHO lower amounts of ectopic fat (visceral and liver), and higher leg fat deposition, expandability of subcutaneous adipose tissue, preserved insulin sensitivity, and beta-cell function as well as better cardiorespiratory fitness compared to unhealthy obesity. Whereas the absence of metabolic abnormalities may reduce the risk of type 2 diabetes and cardiovascular diseases in metabolically healthy individuals compared to unhealthy individuals with obesity, it is still higher in comparison with healthy lean individuals. In addition, MHO seems to be a transient phenotype further justifying therapeutic weight loss attempts—even in this subgroup—which might not benefit from reducing body weight to the same extent as patients with unhealthy obesity. Metabolically healthy obesity represents a model to study mechanisms linking obesity to cardiometabolic complications. Metabolically healthy obesity should not be considered a safe condition, which does not require obesity treatment, but may guide decision-making for a personalized and risk-stratified obesity treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hyperplasia, referring to an increase in the number of adipocytes, is associated with an increase in subcutaneous fat volume and protective signals, and is associated with MHO (50).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“On the contrary, hypertrophic adipocytes, in which existing adipocytes enlarge, is associated with increased dysfunction and MUHO (50), which contributes to IR and subsequent T2D (52, 53).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126 · cited 7×
“8 Endocrine Reviews, June 2020, 41(3):1–16 Blüher Metabolically Healthy Obesity sex hormones may play a role in the transition from MHO to MUO.”
BackgroundInfluentialSelf-citationThe global obesity pandemic: shaped by global drivers and local environments
Swinburn, B. A., Sacks, G., Hall, K. D., McPherson, K., Finegood, D. T., Moodie, M. L., & Gortmaker, S. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60813-1 · Cited by 4,888
Cited by
Items 101–200 of 999
An Overview on the Effects of Some Carotenoids on Health: Lutein and Zeaxanthin
Şanlıer, N., Yıldız, E., & Özler, E. (2024) · Current Nutrition Reports · doi:10.1007/s13668-024-00579-z · Cited by 37
“While the prevalence of obesity has increased three-fold in adults since the 1970s, it has also increased dramatically in children and adolescents [50].”
Saadati, S., Naseri, K., Asbaghi, O., Yousefi, M., Golalipour, E., & de Courten, B. V. (2023) · Obesity Reviews · doi:10.1111/obr.13667 · Cited by 40
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
Abad‐Jiménez, Z., López‐Domènech, S., Díaz‐Rúa, R., Iannantuoni, F., Gómez‐Abril, S. Á., Periañez-Gómez, D., Morillas, C., Víctor, V. M., & Rocha, M. (2020) · Antioxidants · doi:10.3390/antiox9090892 · Cited by 38
“It is now thought that MHO is a transient phenotype that can turn into unhealthy metabolic obesity during the natural course of the disease [9].”
BackgroundVerboven, K., & Hansen, D. (2020) · Sports Medicine · doi:10.1007/s40279-020-01392-8 · Cited by 40
Influence of dietary patterns on the metabolically healthy obesity phenotype: A systematic review
Vilela, D. L. D. S., da Fonseca, P. G., Pinto, S. L., & Bressan, J. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.05.007 · Cited by 39
Kananen, L., Eriksdotter, M., Boström, A., Kivipelto, M., Annetorp, M., Metzner, C., Jerlardtz, V. B., Engström, M., Johnson, P., Lundberg, L. G., et al. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.07.025 · Cited by 38
Hu, K., Edelen, E. D., Zhuo, W., Khan, A. A., Orbegoso, J., Greenfield, L., Rahi, B., Griffin, M. J., Ilich, J. Z., & Kelly, O. J. (2023) · Metabolites · doi:10.3390/metabo13101056 · Cited by 35
“Metabolically healthy obesity/obese (MHO) is a high BMI with serum triglycerides, cholesterol, blood pressure, and fasting blood glucose within the healthy range without medication [29].”
BackgroundCirculating cell adhesion molecules in metabolically healthy obesity
Mulhem, A., Moulla, Y., Klöting, N., Ebert, T., Tönjes, A., Faßhauer, M., Dietrich, A., Schön, M. R., Stümvoll, M., Richter, V., et al. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-00667-4 · Cited by 32
Self-citationChew, N., Kong, G., Venisha, S., Chin, Y. H., Ng, C. H., Muthiah, M. D., Khoo, C. M., Chai, P., Kong, W. K. F., Poh, K. K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.05.007 · Cited by 39
Pelczyńska, M., Miller‐Kasprzak, E., Piątkowski, M., Mazurek, R., Klause, M., Suchecka, A., Bucoń, M., & Bogdański, P. (2023) · Antioxidants · doi:10.3390/antiox12122046 · Cited by 40
The evolution of the understanding of obesity over the last 100 years
Gómez‐Ambrosi, J., Catalán, V., & Frühbeck, G. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01668-3 · Cited by 44
“…abnormalities is often used to de fi ne health status in individuals with obesity, there is currently no consensus on which speci fi c metabolic markers should be included, making it dif fi cult to accurately estimate the true prevalence of metabolically healthy or unhealthy obesity phenotypes [86].”
Heindel, J. J., Alvarez, J. A., Atlas, E., Cave, M. C., Chatzi, V. L., Collier, D. N., Corkey, B. E., Fischer, D. K., Goran, M. I., Howard, S. G., et al. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.05.024 · Cited by 40
Garske, K. M., Kar, A., Comenho, C., Balliu, B., Pan, D. Z., Bhagat, Y. V., Rosenberg, G. M., Koka, A., Das, S. S., Miao, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39919-y · Cited by 33
Obesity: a 100 year perspective
Bray, G. A. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01530-6 · Cited by 44
“Healthy versus unhealthy obesity is another phenotype that has been used to categorize obesity [47].”
Yao, F., Cui, J., Shen, Y., Jiang, Y., Li, Y., Liu, X., Feng, H., Jiao, Z., Liu, C., Hu, F., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-20631-5 · Cited by 34
“Approximately 10–30% of obese individuals are classified as metabolically healthy, contributing to the complexity of the "obesity paradox" [8, 9].”
All-cause mortality in metabolically healthy individuals was not predicted by overweight and obesity
Tian, Q., Wang, A., Zuo, Y., Chen, S., Hou, H., Wang, W., Wu, S., & Wang, Y. (2020) · JCI Insight · doi:10.1172/jci.insight.136982 · Cited by 32
Range of adiposity and cardiorenal syndrome
Pazos, F. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i8.322 · Cited by 35
Cardiovascular Disease Risk Reduction and Body Mass Index
Samson, R., Ennezat, P. V., Jemtel, T. H. L., & Oparil, S. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01213-5 · Cited by 33
Reduced leukocyte mitochondrial copy number in metabolic syndrome and metabolically healthy obesity
Agius, R., Pace, N. P., & Fava, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.886957 · Cited by 32
“Crucially, MHO is considered a transient phenotype having a high prevalence in premenopausal women, which can shift to a metabolically-unhealthy phenotype during the natural course of obesity and in response to obesity management (88, 89).”
BackgroundEffects of female obesity on conception, pregnancy and the health of offspring
Wei, W., Zhang, X., Zhou, B., Ge, B., Tian, J., & Chen, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.949228 · Cited by 43
“Adults with a BMI of ≥ 25 are regarded as overweight, whereas those with a BMI of ≥ 30 as obese (1).”
BackgroundAn overview of diabetes mellitus in pregnant women with obesity
Bashir, M., Fagier, Y., Ahmed, B., & Konje, J. C. (2024) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2024.102469 · Cited by 45
Lung cancer and obesity: A contentious relationship (Review)
Georgakopoulou, V., Lempesis, I. G., Τράκας, Ν., Sklapani, P., He, Y., & Spandidos, D. A. (2024) · Oncology Reports · doi:10.3892/or.2024.8817 · Cited by 35
Overweight and obesity in domestic cats: epidemiological risk factors and associated pathologies
Saavedra, C., Pérez, C., Oyarzun, C. E., & Torres, Á. (2024) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x241285519 · Cited by 43
Stratakis, N., Anguita‐Ruiz, A., Fabbri, L., Maître, L., González, J. R., Andrušaitytė, S., Basagaña, X., Borràs, E., Keun, H. C., Chatzi, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56013-7 · Cited by 47
“It has been suggested that complex interactions between meta-bolicallyactivetissues(suchasfat,liver,andtheskeletalmuscle)playa roleinthehealthstateofthecomplexobesityphenotype 6,7 .”
Chen, H., Tang, N., Ye, Q., Yu, X., Yang, R., Cheng, H., Zhang, G., & Zhou, X. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1012028 · Cited by 29
“Although there is no universal definition, MHO is generally characterized by a BMI ≥30 kg/m2 without overt cardiometabolic syndromes at the time of diagnosis (Blüher, 2020).”
BackgroundA high-sugar diet, but not obesity, reduces female fertility in Drosophila melanogaster
Nunes, R. D., & Drummond‐Barbosa, D. (2023) · Development · doi:10.1242/dev.201769 · Cited by 34
Lampignano, L., Zupo, R., Donghia, R., Guerra, V., Castellana, F., Murro, I., Noia, C. D., Sardone, R., Giannelli, G., & Pergola, G. D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241841 · Cited by 34
“This inverse association was confirmed also in MHO and Metabolic Syndrome subgroups.”
BackgroundMethodInfluentialConversions between metabolically unhealthy and healthy obesity from midlife to late-life
Ler, P., Lindfors, E. O., Zhan, Y., Finkel, D., Aslan, A. K. D., & Karlsson, I. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01425-y · Cited by 31
Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality
Oh, R., Kim, S., Cho, S. H., Kim, J., Lee, Y., Jin, S., Hur, K. Y., Kim, G., & Kim, J. H. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0042 · Cited by 35
Mohaghegh, N., Iyer, A., Wang, E., Balajam, N. Z., Kang, H., Akbari, M., Barnhill, M. S., Khademhosseini, A., Pearson, R. M., & Najafabadi, A. H. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113670 · Cited by 31
Beyond BMI: Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine
Tănăsescu, M., Rosu, A.-M., Mincă, A., Rosu, A.-L., Grigorie, M., Timofte, D., & Ionescu, D. (2025) · Diagnostics · doi:10.3390/diagnostics15233025 · Cited by 41
Ebert, T., Painer, J., Bergman, P., Qureshi, A. R., Giroud, S., Stalder, G. L., Kublickiene, K. R., Göritz, F., Vetter, S. G., Bieber, C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76346-1 · Cited by 29
Ramos-López, O., Milton‐Laskibar, I., & Martínez, J. A. (2021) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000754 · Cited by 29
Zhang, X., Zhu, J., Kim, J. H., Sumerlin, T. S., Feng, Q., & Yu, J. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01025-w · Cited by 36
Gao, X., Sun, G., Randell, E. W., Tian, Y., & Zhou, H. (2020) · Food & Function · doi:10.1039/d0fo01743d · Cited by 27
T cell phenotypes associated with insulin resistance: results from the Berlin Aging Study II
Sbierski‐Kind, J., Goldeck, D., Buchmann, N., Spranger, J., Volk, H., Steinhagen‐Thiessen, E., Pawelec, G., Demuth, I., & Spira, D. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-00211-y · Cited by 28
Potential role of anti-inflammatory HDL subclasses in metabolic unhealth/obesity
Tang, H., Xiang, Z., Li, L., Shao, X., Zhou, Q., You, X., Xiong, C., Ning, J., Chen, T., Deng, D., et al. (2021) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2021.1961798 · Cited by 27
Mir, F. A., Mall, R., Iskandarani, A., Ullah, E., Samra, T. A., Cyprian, F. S., Parray, A., Alkasem, M., Abdalhakam, I., Farooq, F., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.937089 · Cited by 32
“Over the past years, some biological mechanisms and phenotypic characteristics have been identified that differentiate individuals with OBO from OBM (11).”
BackgroundRelationship between obesity severity, metabolic status and cardiovascular disease in obese adults
Liu, Y., Douglas, P. S., Lip, G. Y. H., Thabane, L., Li, L., Ye, Z., & Li, G. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13912 · Cited by 27
Barrea, L., Verde, L., Simancas‐Racines, D., Zambrano, A. K., Frías-Toral, E., Colao, A., Savastano, S., & Muscogiuri, G. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04546-0 · Cited by 30
“In addition, the metabolic phenotype of obesity is influenced by adipose tissue distribution, which plays a central role in promoting metabolic and cardiovascular deterioration [14].”
BackgroundFactors Associated With Semaglutide Initiation Among Adults With Obesity
Podolsky, M. I., Raquib, R., Shafer, P. R., Hempstead, K., Ellis, R. P., & Stokes, A. C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.55222 · Cited by 26
Jurado‐Fasoli, L., Sánchez‐Delgado, G., Alcántara, J. M. A., Acosta, F. M., Sánchez, R. S., Labayen, I., Ortega, F. B., Martínez‐Téllez, B., & Ruiz, J. R. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2023.104948 · Cited by 27
“12 Indeed, despite individuals with MHOO have a lower risk of all-cause mortality than MUOO, they still show a higher risk of all-cause mortality and cardiometabolic diseases than their metabolically healthy normal-weight counterparts.”
BackgroundRethinking weight loss treatments as cardiovascular medicine in obesity, a comprehensive review
Tuccinardi, D., Watanabe, M., Masi, D., Monte, L., Meffe, L. B., Cavallari, I., Nusca, A., Maddaloni, E., Gnessi, L., Napoli, N., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae171 · Cited by 32
Adipose Tissue Plasticity: A Comprehensive Definition and Multidimensional Insight
Mo, Y.-Y., Han, Y., Xu, S., Jiang, H., Wu, H., Cai, J., Li, L., Bu, Y., Xiao, F., Liang, H., et al. (2024) · Biomolecules · doi:10.3390/biom14101223 · Cited by 35
Circulating prolactin level is increased in metabolically healthy obesity
Liu, J., Zhang, L., Fu, J. H., Wang, Q., & Wang, G. (2021) · Endocrine Connections · doi:10.1530/ec-21-0040 · Cited by 30
Lee, A. A., & Den Hartigh, L. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1682231 · Cited by 32
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
“33 39-41 Interestingly, the phenotypic subtypes featuring whole-body and adipose tissue insulin resistance, the severe insulin-resistant diabetes (SIRD) and the mild obesity-related diabetes (MOD), also have the highest prevalence of MASLD.”
BackgroundMiller, C., Madden-Doyle, L., Jayasena, C., McIlroy, M., Sherlock, M., & O’Reilly, M. W. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae128 · Cited by 28
Albrecht, M., Worthmann, A., Heeren, J., Diemert, A., & Arck, P. (2025) · Seminars in Immunopathology · doi:10.1007/s00281-024-01033-6 · Cited by 31
“Of note, a proportion of individuals with OWO are considered metabolically healthy; this is a transient state that can flip towards metabolic impairment and back, depending on diet and lifestyle [4].”
Leone, A., Amicis, R. S. D., Battezzati, A., & Bertoli, S. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.858206 · Cited by 29
“one in five obese women in our sample had this metabolic phenotype (9, 13), but the prevalence was influenced by age.”
BackgroundPrognostically Distinct Phenotypes of Metabolic Health Beyond Obesity in Aortic Stenosis
Chew, N., Zhang, A. A. Y., Kong, G., Lee, K. L., Ng, C. H., Chong, B., Ngiam, J. N., Sia, C., Loh, P. H., Lim, Y., et al. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.05.018 · Cited by 25
Wang, W., Wang, F., Li, Y., Shi, Y., Wang, X., Chen, X., Zheng, W., Hsing, J. C., Lü, Y., Wu, Y., et al. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13644 · Cited by 26
Metabolically healthy obesity: is there a link with polyunsaturated fatty acid intake and status?
Arsić, A., Takić, M. M., Kojadinović, M., Petrović, S., Paunović, M., Vučić, V., & Ristić-Medić, D. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2020-0317 · Cited by 24
Kesztyüs, D., Lampl, J., & Kesztyüs, T. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111070 · Cited by 35
“Most researchers agree that metabolically healthy obesity is a transient condition that sooner or later progresses into metabolically unhealthy obesity [53,62,63].”
BackgroundInfluentialIron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target
Chen, H. (2022) · Liver Research · doi:10.1016/j.livres.2022.09.003 · Cited by 27
Evolving perspectives on evaluating obesity: from traditional methods to cutting-edge techniques
Wang, H., Qin, Y., Niu, J., Chen, H., Lu, X., Wang, R., & Han, J. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2472856 · Cited by 31
“A key factor underpinning the difference in CVD risk between individuals with MONW and MHO is the likely presence of excess VAT [59,60].”
Tutunchi, H., Naeini, F., Ebrahimi‐Mameghani, M., Najafipour, F., Mobasseri, M., & Ostadrahimi, A. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101754 · Cited by 25
Zheng, X., Peng, R., Xu, H., Lin, T., Qiu, S., Wei, Q., Yang, L., & Ai, J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.783660 · Cited by 29
“With age- and gender-dependent prevalence of 10–30% (13), MHO is not rare even though the variation of prevalence is high across cohort studies (14, 15), which is mostly caused by the different MHO criteria.”
BackgroundDifferences in the gut microbiome by physical activity and BMI among colorectal cancer patients.
Himbert, C., Stephens, W. Z., Gigic, B., Hardikar, S. S., Holowatyj, A. N., Lin, T., Ose, J., Swanson, E., Ashworth, A., Warby, C. A., et al. (2022) · PubMed · Cited by 34
Metabolically Healthy Obesity: Are Interventions Useful?
Mathis, B. J., Tanaka, K., & Hiramatsu, Y. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00494-4 · Cited by 28
Body weight in neurological and psychiatric disorders: a large prospective cohort study
Wang, R., He, Y., Deng, Y., Wang, H.-F., Zhang, Y., Feng, J., Cheng, W., & Yu, J. (2024) · Nature Mental Health · doi:10.1038/s44220-023-00158-1 · Cited by 29
Mitchelson, K. A. J., O’Connell, F., O'Sullivan, J. N., & Roche, H. M. (2024) · Metabolites · doi:10.3390/metabo14010042 · Cited by 29
“For example, for an equivalent body weight or body mass index (BMI), some people are profoundly insulin resistant at a given body weight/adiposity, while others remain insulin sensitive [4].”
BackgroundLipedema: A Disease Triggered by M2 Polarized Macrophages?
Grewal, T., Kempa, S., & Buechler, C. (2025) · Biomedicines · doi:10.3390/biomedicines13030561 · Cited by 27
“Hence, lipedema patients remain insulin-sensitive, display normal blood pressure and almost normal blood lipid levels, and do not store excess fat in the liver [6–8].”
Pre-fertilization-origin preservation of brown fat-mediated energy expenditure in humans
Yoneshiro, T., Matsushita, M., Fuse-Hamaoka, S., Kuroiwa, M., Kurosawa, Y., Yamada, Y., Arai, M., Wei, Y., Iida, M., Kuma, K., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01249-2 · Cited by 27
Miracle Berry as a Potential Supplement in the Control of Metabolic Risk Factors in Cancer
de Cedrón, M. G., Wagner, S., Reguero, M., Menéndez‐Rey, A., & de Molina, A. R. (2020) · Antioxidants · doi:10.3390/antiox9121282 · Cited by 27
ASCs and their role in obesity and metabolic diseases
Milan, G., Conci, S., Sanna, M., Favaretto, F., Bettini, S., & Vettor, R. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.09.001 · Cited by 24
Calcaterra, V., Biganzoli, G., Ferraro, S., Verduci, E., Rossi, V., Vizzuso, S., Bosetti, A., Borsani, B., Biganzoli, E. M., & Zuccotti, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071856 · Cited by 25
Depression status and insulin resistance in adults with obesity: A cross-sectional study
He, Y., Li, T., Guo, F., Zhao, S., Zhang, J., Guo, X., Tao, Y., Lin, X., & Jin, L. (2022) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2022.111049 · Cited by 22
Retnakaran, R. R., & Shah, B. R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02581-0 · Cited by 25
“The downstream nature of these risk factors is evident in current thinking that metabolically healthy obesity generally requires transition of metabolically unhealthy obesity for the manifestation of incident CVD risk [24].”
BackgroundHe, Z., Fu, T., Lu, S., Sun, Y., Zhang, Y., Shi, W., Li, Z., Deng, M., Chen, J., & Bai, Y. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12468 · Cited by 28
“16,17 Obesity has been reported to relate to multiple chronic diseases through metabolic homeostasis and inflammation, 18,19 but has not been explored regarding IBD.”
BackgroundCorrelation analysis of obesity phenotypes with leptin and adiponectin
Aisike, G., Kuerbanjiang, M., Muheyati, D., Zaibibuli, K., Lv, M.-X., & Han, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-43550-8 · Cited by 24
“Interestingly, not all obese individuals present with metabolic abnormalities such as hypertension, hyperlipidemia, diabetes and insulin resistance, which has been called “metabolically healthy obesity” (MHO) 4,5 .”
BackgroundInflammatory protein signatures in individuals with obesity and metabolic syndrome
Mir, F. A., Abdesselem, H., Cyprian, F. S., Iskandarani, A., Doudin, A., Samra, T. A., Alkasem, M., Abdalhakam, I., Taheri, S., & Abou‐Samra, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-49643-8 · Cited by 24
Chen, T., Cheng, Y. D., Zheng, S., Zhang, G., Zeng, T., & Chao, H. (2024) · BMC Public Health · doi:10.1186/s12889-024-19265-4 · Cited by 22
“Obesity is frequently associated with metabolic syndrome, which includes insulin resistance, hypertension, and lipid abnormalities [23–25].”
BackgroundLewandowska, A., Rudzki, G., Lewandowski, T., Bartosiewicz, A., Próchnicki, M., Stryjkowska-Góra, A., Laskowska, B. J., Sierpińska, M., Rudzki, S., & Pavlov, S. V. (2025) · BMC Public Health · doi:10.1186/s12889-025-21591-0 · Cited by 21
Zhao, F., Yue, Z., Zhang, L., Qi, Y., Sun, Y., Wang, S., & Tian, Q. (2025) · Journal of Innate Immunity · doi:10.1159/000546476 · Cited by 25
Zoghi, G., Shahbazi, R., Mahmoodi, M., Nejatizadeh, A., & Kheirandish, M. (2021) · BMC Public Health · doi:10.1186/s12889-021-12107-7 · Cited by 21
“Metabolic health has been referred to as the absence of all the components of MetS by some researchers and not meeting the criteria for the diagnosis of MetS by many others [30].”
BackgroundTang, D., Xiao, X., Chen, L., Kangzhu, Y., Deng, W., Basang, Yang, S., Long, L., Xie, X., Lu, J., et al. (2022) · British Journal Of Nutrition · doi:10.1017/s0007114521005158 · Cited by 22
Rosso, M. C., Stilo, F., Squara, S., Liberto, E., Mai, S., Mele, C., Marzullo, P., Aimaretti, G., Reichenbach, S. E., Collino, M., et al. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-020-03008-6 · Cited by 27
Teke, J., Msiska, M., Adanini, O., Egbon, E., Osborne, A., & Olawade, D. B. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100657 · Cited by 25
Metabolically healthy obesity and physical fitness in military males in the CHIEF study
Wang, S., Chung, P.-S., Lin, Y., Tsai, K., Lin, S.-C., Fan, C.-H., Lin, Y., & Lin, G. (2021) · Scientific Reports · doi:10.1038/s41598-021-88728-0 · Cited by 21
Katsiki, N., Kouvari, M., Panagiotakos, D. B., Borghi, C., Chrysohoou, C. A., Mikhailidis, D. P., & Pitsavos, C. S. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203108 · Cited by 20
Do Temporal Eating Patterns Differ in Healthy versus Unhealthy Overweight/Obese Individuals?
Mazri, F. H., Manaf, Z. A., Shahar, S., Ludin, A. F. M., Karim, N. A., Hazwari, N., Kek, Q., Basir, S. M. A., & Arifin, A. (2021) · Nutrients · doi:10.3390/nu13114121 · Cited by 27
Serum Bilirubin Level Is Increased in Metabolically Healthy Obesity
Fu, J., Wang, Q., Zhang, L., Liu, J., & Wang, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.792795 · Cited by 21
“43% in our study population, which was lower than previously reported occurrence rate (10%-30%) (5).”
BackgroundResultZhang, Q., Xie, L., Zhang, H., Liu, J., Zhao, Y., Chen, L., Ju, Y., Chen, A., Wang, N., Song, Q., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.820023 · Cited by 30
“Obesity is a heterogeneous condition, and some obese individuals can be metabolically healthy (10).”
BackgroundThe emerging roles of PHOSPHO1 and its regulated phospholipid homeostasis in metabolic disorders
Liu, Y., Wu, Y., & Jiang, M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.935195 · Cited by 22
“The serum level of diacyl-phosphatidylcholine C32:1 was positively associated with healthy metabolic parameters, whereas those of diacyl-phosphatidylcholine C32:2 and C34:2 were positively associated with unhealthy metabolic parameters in obese subjects (Bagheri et al., 2018; Blüher, 2020).”
BackgroundLi, D., Xing, Z., Yu, T., Dong, W., Wang, Z., Peng, C. Y., & Yang, C. (2022) · Food & Function · doi:10.1039/d2fo01450e · Cited by 21
Valenzuela, P. L., Santos‐Lozano, A., Saco‐Ledo, G., Castillo‐García, A., & Lucía, A. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad204 · Cited by 27
Johnson, C., Drummer, C., Shan, H., Shao, Y., Sun, Y., Lu, Y., Saaoud, F., Xu, K., Nanayakkara, G., Fang, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.619951 · Cited by 26
“While the classical model of obesity (metabolically unhealthy obesity) is often associated with the comorbidities mentioned above, there exists a subset of obese individuals who do not present with these metabolic dysfunction-related comorbidities and are thus referred to as metabolically healthy obese (5).”
BackgroundOnay, T., Bekar, D., Çoban, E., Doğan, N., & Günşen, U. (2025) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.70135 · Cited by 21
Cataldi, S., Aprile, M., Melillo, D., Mucel, I., Giorgetti‐Peraldi, S., Cormont, M., Italiani, P., Blüher, M., Tanti, J., Ciccodicola, A., et al. (2021) · Cells · doi:10.3390/cells11010042 · Cited by 21
“Of note, the alteration of spliceosome machinery due to altered levels of phosphorylated proteins involved in mRNA splicing has been recently reported even in the context of obesity and T2D [55–57].”
BackgroundSelf-citationArmborst, D., Bitterlich, N., Alteheld, B., Rösler, D., Metzner, C., & Siener, R. (2021) · Nutrients · doi:10.3390/nu14010077 · Cited by 21
“Moreover, an impaired ability to expand subcutaneous fat resulted in metabolically unhealthy phenotypes [46,47].”
BackgroundLong-term metabolic fate and mortality in obesity without metabolic syndrome
Käräjämäki, A. J., Korkiakoski, A., Hukkanen, J., Kesäniemi, Y. A., & Ukkola, O. H. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2075915 · Cited by 19
Mechanism of immune attack in the progression of obesity-related type 2 diabetes
Wang, H., Tang, J., Sun, L., Li, Z., Deng, M., & Dai, Z. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.494 · Cited by 22
Patient Perceptions of Weight Stigma Experiences in Healthcare: A Qualitative Analysis
Robinson, K. M., Robinson, K. A., Scherer, A. M., & Mackin, M. L. (2024) · Health Expectations · doi:10.1111/hex.70013 · Cited by 27
Baek, S., & Yoon, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111540 · Cited by 23
Ortiz, G. U., da Silva, L. S. L., Gonçalves, L. D. S., Abud, G. F., Venturini, A. C. R., da Silva, A. S. R., & de Freitas, E. C. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.03.051 · Cited by 24
Dietary control of peripheral adipose storage capacity through membrane lipid remodelling
Tol, M. J., Shimanaka, Y., Bedard, A. H., Sapia, J. L., Cui, L., Colaço-Gaspar, M., Hofer, P., Ferrari, A., Qian, K., Kennelly, J. P., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01320-y · Cited by 28
“It has been posited that a high degree of adipose tissue plasticity underlies metabolically healthy obesity 9,10 .”
RETRACTED: HOXA5-miR-574-5p axis promotes adipogenesis and alleviates insulin resistance
Li, Y., Li, J., Yu, H., Liu, Y., Song, H., Tian, X., Liu, D., Yan, C., & Han, Y. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.08.031 · Cited by 18
RetractedDamanhoury, S., Morrison, K. M., Mian, R. I., McPhee, P. G., Kozyrskyj, A. L., Newton, A. S., Buchholz, A., Chanoine, J., Hamilton, J. K., Ho, J., et al. (2021) · Clinical Obesity · doi:10.1111/cob.12490 · Cited by 20
Metadata
- Authors
- Blüher, M.
- Affiliations
- Helmholtz Munich (DE)
- Corresponding author
- Blüher, Matthias
- ORCID
- Blüher, Matthias
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-03-04
- Volume
- 41
- Issue
- 3
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7098708
- OpenAlex
- W3009496837
- Cited by
- 1,090
- References
- 123
- Citations by year
- 2026: 197 · 2025: 222 · 2024: 213 · 2023: 162 · 2022: 155 · 2021: 105 · 2020: 35
- FWCI
- 86.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion, cc-by)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (209933838)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- metabolically healthy obesity, obesity, cardiometabolic risk, type 2 diabetes, cardiovascular disease, insulin sensitivity, beta-cell function, ectopic fat, visceral fat, liver fat, leg fat, cardiorespiratory fitness, weight loss, obesity treatment, risk stratification
- MeSH terms
- Obesity, Metabolically Benign, Cardiometabolic Risk Factors, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Obesity, Metabolic Syndrome, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.